AUTL:NSD-Autolus Therapeutics Ltd (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 3.73

Change

0.00 (0.00)%

Market Cap

USD 0.99B

Volume

0.75M

Analyst Target

USD 26.33
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom. Address: The Mediaworks, London, United Kingdom, W12 7FP

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

N/A

USD 126.22B
VRTX Vertex Pharmaceuticals Inc

N/A

USD 120.00B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 35.16B
ARGX argenx NV ADR

N/A

USD 32.02B
MRNA Moderna Inc

N/A

USD 25.25B
BGNE BeiGene Ltd

N/A

USD 22.45B
SMMT Summit Therapeutics PLC

N/A

USD 17.92B
RPRX Royalty Pharma Plc

N/A

USD 16.34B
UTHR United Therapeutics Corporatio..

N/A

USD 15.71B
PCVX Vaxcyte Inc

N/A

USD 14.50B

ETFs Containing AUTL

HOML 8.77 % 0.00 %

N/A

N/A
CLAW 6.09 % 0.95 %

N/A

N/A
ITB 4.25 % 0.42 %

N/A

N/A
XHB SPDR® S&P Homebuilders E.. 3.50 % 0.35 %

N/A

N/A
RFG Invesco S&P MidCap 400® .. 2.15 % 0.35 %

N/A

N/A
FXD First Trust Consumer Disc.. 1.75 % 0.64 %

N/A

USD 1.48B
VAMO 1.67 % 0.64 %

N/A

N/A
AFMC First Trust Active Factor.. 1.55 % 0.00 %

N/A

USD 0.01B
ZEUS:CA 1.40 % 0.73 %

N/A

N/A
EZM WisdomTree U.S. MidCap Ea.. 1.20 % 0.38 %

N/A

N/A
MDYG SPDR® S&P 400 Mid Cap Gr.. 1.05 % 0.15 %

N/A

N/A
IVOG Vanguard S&P Mid-Cap 400 .. 1.03 % 0.20 %

N/A

USD 1.09B
IJK iShares S&P Mid-Cap 400 G.. 1.03 % 0.24 %

N/A

USD 9.62B
QVMM Invesco Exchange-Traded F.. 0.63 % 0.00 %

N/A

USD 0.32B
ONEO SPDR® Russell 1000 Momen.. 0.55 % 0.20 %

N/A

N/A
WDSC:LSE SPDR MSCI World Small Cap.. 0.21 % 0.00 %

N/A

N/A
WOSC:LSE SPDR MSCI World Small Cap.. 0.21 % 0.00 %

N/A

N/A
WLDS:LSE iShares MSCI World Small .. 0.19 % 0.00 %

N/A

N/A
WSML:LSE iShares MSCI World Small .. 0.19 % 0.00 %

N/A

N/A
IUSN:F iShares MSCI World Small .. 0.19 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -42.08% 31% F 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -42.08% 31% F 19% F
Trailing 12 Months  
Capital Gain 59.40% 77% C+ 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 59.40% 77% C+ 87% B+
Trailing 5 Years  
Capital Gain -71.63% 46% F 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -71.63% 46% F 18% F
Average Annual (5 Year Horizon)  
Capital Gain -1.49% 53% F 39% F
Dividend Return -1.49% 52% F 36% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 78.81% 41% F 22% F
Risk Adjusted Return -1.89% 52% F 38% F
Market Capitalization 0.99B 80% B- 71% C-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector